AbbVie

-13.15%

Live  

AbbVie is a global, research-driven biopharmaceutical company that was founded in 2013 when it spun off from Abbott Laboratories. The company's focus is on developing advanced therapies and medicines for conditions such as immunology, oncology, neuroscience, and virology.
Headquartered in North Chicago, Illinois, AbbVie employs approximately 48,000 people worldwide and operates in more than 75 countries. The company is dedicated to providing innovative, safe, and effective treatments for patients, and its products are available in over 170 countries.
AbbVie's mission is to discover and deliver breakthrough medicines that enable people to live better lives. The company's values include integrity, collaboration, innovation, and a commitment to patient well-being. AbbVie has a strong pipeline of medications in various stages of development, and the company invests heavily in research and development to bring new treatments to patients.
Some of AbbVie's notable products include Humira, the best-selling prescription medication in the world, used to treat autoimmune conditions such as rheumatoid arthritis and Crohn's disease, and Imbruvica, a targeted therapy for certain types of cancers. The company also has a portfolio of other medicines and treatments for conditions such as hepatitis C, multiple sclerosis, and Parkinson's disease.
AbbVie is committed to giving back to communities by supporting various charitable and scientific organizations. The company's philanthropic efforts focus on initiatives that align with its areas of expertise, such as healthcare, education, and environmental sustainability.
In addition to its focus on research and patient care, AbbVie is also committed to operating ethically and responsibly. The company has stated its commitment to reducing its environmental impact, promoting diversity and inclusion, and upholding rigorous ethical standards in all its operations.
Overall, AbbVie is a leading, globally recognized biopharmaceutical company with a strong portfolio and a commitment to making a positive impact in the world.

AbbVie is a big company that creates medicines and treatments to help people with different health problems. They focus on serious illnesses like arthritis, cancer, and even certain types of skin conditions. You know how sometimes people need to take a pill or get an injection to feel better? Well, AbbVie makes those kinds of medicines.
AbbVie makes money in a few ways. First, they spend a lot of time and money researching and testing new medicines to make sure they work well and are safe for people to use. When they find something that works, they get special permission from the government to sell it, and then they can sell those medicines to hospitals, pharmacies, and doctors. When doctors give those medicines to patients, AbbVie gets paid for them.
Now, why is AbbVie successful? One big reason is that they have some really important and effective medicines people need. The more people that need the medicine, the more money the company makes. Plus, AbbVie is always working on new treatments and finding better ways to help people, which keeps them moving forward.
In the future, AbbVie is likely to stay successful because they continue to invest in research and development. They also have many patents, which are like special rights that let them sell their medicines without competition for a certain time. This means they can earn money while others can’t sell the same product. Plus, as more people in the world get older, they might need more medicines, which means AbbVie can be there to help and earn money at the same time. By continuing to innovate and keep people healthy, AbbVie is set up for success in the years to come.

VGhlcmUgYX JlIHNldmVy YWwgbm90ZX dvcnRoeSBh c3BlY3RzIG 9mIHRoZSBB YmJWaWUgY2 9tcGFueSB0 aGF0IG1ha2 UgaXQgc3Rh bmQgb3V0IG Zyb20gb3Ro ZXIgcGhhcm 1hY2V1dGlj YWwgY29tcG FuaWVzOjxi cj4xLiBGb2 N1cyBvbiBp bm5vdmF0aX ZlIHJlc2Vh cmNoIGFuZC BkZXZlbG9w bWVudDogQW JiVmllIHBs YWNlcyBhIH N0cm9uZyBl bXBoYXNpcy BvbiBkaXNj b3ZlcmluZy BhbmQgZGV2 ZWxvcGluZy BuZXcgdHJl YXRtZW50cy Bmb3IgY2hh bGxlbmdpbm cgaGVhbHRo IGNvbmRpdG lvbnMuIFRo ZSBjb21wYW 55IGludmVz dHMgaGVhdm lseSBpbiBy ZXNlYXJjaC BhbmQgZGV2 ZWxvcG1lbn QsIHdpdGgg YSBzaWduaW ZpY2FudCBw b3J0aW9uIG 9mIGl0cyBy ZXZlbnVlIG JlaW5nIGFs bG9jYXRlZC B0byB0aGlz IGFyZWEuPG JyPjIuIFN0 cm9uZyBwb3 J0Zm9saW8g b2YgbGVhZG luZyBtZWRp Y2luZXM6IE FiYlZpZSBo YXMgYSByb2 J1c3QgcG9y dGZvbGlvIG 9mIG1lZGlj aW5lcyB0aG F0IGFkZHJl c3MgYSBkaX ZlcnNlIHJh bmdlIG9mIG Rpc2Vhc2Vz LCBpbmNsdW RpbmcgaW1t dW5vbG9neS wgbmV1cm9s b2d5LCBvbm NvbG9neSwg YW5kIHZpcm 9sb2d5LiBN YW55IG9mIG l0cyBwcm9k dWN0cyBhcm UgY29uc2lk ZXJlZCBiZX N0LWluLWNs YXNzIGluIH RoZWlyIHJl c3BlY3Rpdm UgdGhlcmFw ZXV0aWMgYX JlYXMuPGJy PjMuIFN0cm 9uZyBwaXBl bGluZTogSW 4gYWRkaXRp b24gdG8gaX RzIGN1cnJl bnQgbGluZS BvZiBtZWRp Y2luZXMsIE FiYlZpZSBo YXMgYSBzdH JvbmcgcGlw ZWxpbmUgb2 YgcG90ZW50 aWFsIG5ldy B0cmVhdG1l bnRzLCB3aG ljaCBpdCBj b250aW51b3 VzbHkgZXZh bHVhdGVzIG ZvciB0aGVp ciBwb3Rlbn RpYWwgdG8g YWRkcmVzcy B1bm1ldCBt ZWRpY2FsIG 5lZWRzIGFu ZCBjcmVhdG UgdmFsdWUg Zm9yIHBhdG llbnRzLjxi cj40LiBDb2 1taXRtZW50 IHRvIHBhdG llbnQgY2Fy ZTogQWJiVm llIGlzIGNv bW1pdHRlZC B0byBtYWtp bmcgYSBtZW FuaW5nZnVs IGRpZmZlcm VuY2UgaW4g dGhlIGxpdm VzIG9mIHBh dGllbnRzIG J5IHByb3Zp ZGluZyBhY2 Nlc3MgdG8g aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgYW 5kIHN1cHBv cnRpbmcgZG lzZWFzZSBl ZHVjYXRpb2 4gYW5kIGF3 YXJlbmVzcy Bwcm9ncmFt cy48YnI+NS 4gU3VzdGFp bmFiaWxpdH kgaW5pdGlh dGl2ZXM6IF RoZSBjb21w YW55IGhhcy BhIHN0cm9u ZyBmb2N1cy BvbiBzdXN0 YWluYWJpbG l0eSBhbmQg aGFzIGltcG xlbWVudGVk IHNldmVyYW wgaW5pdGlh dGl2ZXMgdG 8gcmVkdWNl IGVudmlyb2 5tZW50YWwg aW1wYWN0LC Bwcm9tb3Rl IGVtcGxveW VlIHdlbGwt YmVpbmcsIG FuZCBzdXBw b3J0IGxvY2 FsIGNvbW11 bml0aWVzLj xicj42LiBT dHJvbmcgZm luYW5jaWFs IHBlcmZvcm 1hbmNlOiBB YmJWaWUgaG FzIGNvbnNp c3RlbnRseS BkZWxpdmVy ZWQgc3Ryb2 5nIGZpbmFu Y2lhbCByZX N1bHRzLCB3 aXRoIGEgdH JhY2sgcmVj b3JkIG9mIH N1c3RhaW5h YmxlIGxvbm ctdGVybSBn cm93dGggYW 5kIHNoYXJl aG9sZGVyIH ZhbHVlIGNy ZWF0aW9uLj xicj43LiBH bG9iYWwgcH Jlc2VuY2U6 IEFiYlZpZS BvcGVyYXRl cyBpbiBtb3 JlIHRoYW4g MTc1IGNvdW 50cmllcyBh bmQgaGFzIG Egc3Ryb25n IGdsb2JhbC BwcmVzZW5j ZSwgd2hpY2 ggZW5hYmxl cyBpdCB0by ByZWFjaCBh IHdpZGUgcG F0aWVudCBw b3B1bGF0aW 9uIGFuZCBj b250cmlidX RlIHRvIGlt cHJvdmluZy BnbG9iYWwg aGVhbHRoIG 91dGNvbWVz Lg==

QWJiVmllIG lzIGEgYmlv cGhhcm1hY2 V1dGljYWwg Y29tcGFueS B0aGF0IGZv Y3VzZXMgb2 4gdGhlIGRl dmVsb3BtZW 50LCBtYW51 ZmFjdHVyaW 5nLCBhbmQg Y29tbWVyY2 lhbGl6YXRp b24gb2YgaW 5ub3ZhdGl2 ZSBwaGFybW FjZXV0aWNh bCBwcm9kdW N0cyBwcmlt YXJpbHkgaW 4gdGhlIGFy ZWFzIG9mIG ltbXVub2xv Z3ksIG9uY2 9sb2d5LCBu ZXVyb3NjaW VuY2UsIGFu ZCB2aXJvbG 9neS4gPGJy PlRoZSBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgY2VudG VyZWQgYXJv dW5kIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudCAo UiZEKSBvZi BuZXcgbWVk aWNpbmVzIG FuZCB0aGVy YXBpZXMsIH N0cmF0ZWdp YyBjb2xsYW JvcmF0aW9u cyBhbmQgcG FydG5lcnNo aXBzLCBhbm QgYSBzdHJv bmcgc2FsZX MgYW5kIG1h cmtldGluZy BzdHJhdGVn eSB0byBicm luZyB0aGVz ZSBwcm9kdW N0cyB0byBt YXJrZXQuID xicj5BYmJW aWUncyBSJk QgZWZmb3J0 cyBhcmUgZm 9jdXNlZCBv biBpZGVudG lmeWluZyBw b3RlbnRpYW wgdHJlYXRt ZW50cyBmb3 IgZGlzZWFz ZXMgd2l0aC B0aGUgZ3Jl YXRlc3QgdW 5tZXQgbmVl ZHMsIHVzaW 5nIGN1dHRp bmctZWRnZS B0ZWNobm9s b2dpZXMgYW 5kIGlubm92 YXRpdmUgYX Bwcm9hY2hl cy4gVGhlIG NvbXBhbnkg aGFzIGEgcm 9idXN0IHBp cGVsaW5lIG 9mIHByb21p c2luZyBkcn VnIGNhbmRp ZGF0ZXMgaW 4gdmFyaW91 cyBzdGFnZX Mgb2YgZGV2 ZWxvcG1lbn QuIDxicj5J biBhZGRpdG lvbiwgQWJi VmllIGhhcy Blc3RhYmxp c2hlZCBzdH JhdGVnaWMg Y29sbGFib3 JhdGlvbnMg YW5kIHBhcn RuZXJzaGlw cyB3aXRoIG xlYWRpbmcg b3JnYW5pem F0aW9ucyBp biB0aGUgaG VhbHRoY2Fy ZSBpbmR1c3 RyeSB0byBj b21wbGVtZW 50IGl0cyBp bi1ob3VzZS BSJkQgZWZm b3J0cyBhbm QgYWR2YW5j ZSBpdHMgZH J1ZyBkaXNj b3ZlcnkgYW 5kIGRldmVs b3BtZW50IH Byb2dyYW1z LiBUaGlzIG luY2x1ZGVz IHBhcnRuZX JzaGlwcyB3 aXRoIGFjYW RlbWljIGlu c3RpdHV0aW 9ucywgYmlv dGVjaCBjb2 1wYW5pZXMs IGFuZCBvdG hlciBwaGFy bWFjZXV0aW NhbCBjb21w YW5pZXMuID xicj5BYmJW aWUgYWxzby BoYXMgYSBz dHJvbmcgc2 FsZXMgYW5k IG1hcmtldG luZyBzdHJh dGVneSB0by Bkcml2ZSB0 aGUgY29tbW VyY2lhbCBz dWNjZXNzIG 9mIGl0cyBw cm9kdWN0cy 4gVGhlIGNv bXBhbnkgaG FzIGEgZ2xv YmFsIHByZX NlbmNlIGFu ZCBhIGRpdm Vyc2lmaWVk IHBvcnRmb2 xpbyBvZiBk cnVncywgd2 hpY2ggYWxs b3dzIGl0IH RvIGxldmVy YWdlIGl0cy BvcGVyYXRp b25zIGFuZC ByZXNvdXJj ZXMgaW4gZG lmZmVyZW50 IG1hcmtldH MuIDxicj5P dmVyYWxsLC B0aGUgQWJi VmllIGJ1c2 luZXNzIG1v ZGVsIGlzIG ZvY3VzZWQg b24gZGV2ZW xvcGluZyBh bmQgYnJpbm dpbmcgaW5u b3ZhdGl2ZS BtZWRpY2lu ZXMgdG8gcG F0aWVudHMg aW4gbmVlZC wgd2hpbGUg YWxzbyBkcm l2aW5nIHBy b2ZpdGFibG UgZ3Jvd3Ro IHRocm91Z2 ggc291bmQg UiZELCBwYX J0bmVyc2hp cHMsIGFuZC Bjb21tZXJj aWFsaXphdG lvbiBzdHJh dGVnaWVzLg ==

AI does pose certain risks to AbbVie’s products, services, and competitive positioning, though its impact will depend on various factors.
1. Substitution: AI technology can lead to the development of alternative treatment methods or therapies that could substitute traditional pharmaceutical products. For example, advancements in personalized medicine and gene therapy may provide alternatives to existing AbbVie medications, potentially reducing demand for their products.
2. Disintermediation: The rise of AI-driven platforms can streamline healthcare delivery by facilitating direct patient interactions with AI tools for diagnosis or treatment advice. This could disrupt traditional pharmaceutical sales channels and patient engagement strategies, potentially diminishing the role of companies like AbbVie in patient care and limiting their market reach.
3. Margin Pressure: AI can improve efficiencies in drug discovery, development, and manufacturing, allowing competitors to reduce costs and bring products to market faster. This could exert margin pressure on AbbVie if they do not adapt quickly to these AI advancements. Additionally, AI-driven insights could lead to more effective treatments, increasing competition from companies leveraging these technologies to hold more effective or cheaper alternatives.
While AI presents challenges, it also offers opportunities for AbbVie to enhance its product development, optimize marketing strategies, and improve patient outcomes. The company’s ability to innovate and adapt will be crucial in navigating these risks and maintaining its competitive positioning.

The sensitivity of AbbVie’s earnings, cash flow, and valuation to changes in interest rates can be analyzed through several factors:
1. Earnings Sensitivity: AbbVie’s earnings can be influenced by interest rates primarily through the cost of debt. If interest rates rise, the interest expense on variable-rate debt increases, which can reduce net income. Additionally, higher interest rates may dampen consumer and business spending, potentially impacting sales of AbbVie’s products, especially if they are discretionary or face competition.
2. Cash Flow Sensitivity: Cash flow sensitivity to interest rates mainly arises from financing costs and the overall economic environment. An increase in interest rates could lead to increased costs for servicing debt, which would reduce free cash flow. Conversely, if interest rates rise and signal a stronger economy, it could lead to greater demand for AbbVie’s pharmaceuticals, potentially offsetting some negative impacts.
3. Valuation Sensitivity: The valuation of AbbVie, like most companies, is affected by the discount rate used in discounted cash flow (DCF) models. As interest rates rise, the discount rate increases, leading to a lower present value of future cash flows and thus a lower valuation. Higher interest rates could also lead to a revaluation of risk across the market, leading investors to demand higher returns, which would further impact the stock price.
In summary, AbbVie’s earnings, cash flow, and valuation are sensitive to changes in interest rates, with higher rates posing risks to profitability and valuation, while the extent of the impact will depend on the broader economic context and other mitigating factors such as product demand and operational efficiency.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvWE E4UGdOTTI1 RTBlS3NEVW 1ySEQud2Vi cCIgYWx0PS JBYmJWaWUi IHRpdGxlPS JBYmJWaWUi ICBjbGFzcz 0iaW1nLWZs dWlkIiBoZW lnaHQ9OTAg d2lkdGg9OT AgbG9hZGlu Zz0nbGF6eS cgc3R5bGU9 J2JvcmRlci 1yYWRpdXM6 IDZweDsnPg oKICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdmbGV4 OiAxOyB0ZX h0LWFsaWdu OiBjZW50ZX I7IG1hcmdp bi1sZWZ0Oi A1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPHAgc3R5 bGU9J2Zvbn Qtc2l6ZTog MjZweDsgY2 9sb3I6ICMz MzM7IG1hcm dpbi1ib3R0 b206IDE1cH g7Jz4KICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIPCfk4gg V2FudCB0by ByZWFkIG1v cmUgYWJvdX QgQWJiVmll PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag8J+ZjCBK b2luIG5vdy B0byBnZXQg PGk+IlRoZS BDaGVja2xp c3QgVmFsdW UgSW52ZXN0 b3Ig4oCUIE EgU21hcnRl ciBXYXkgdG 8gUGljayBT dG9ja3MiPC 9pPiBhdCBu byBjb3N0Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvcD4KCi AgICAgICAg ICAgICAgIC AgICAgICAg IDwhLS0KIC AgICAgICAg ICAgICAgIC AgICAgICAg PGRpdiBzdH lsZT0nbWFy Z2luLXRvcD ogMTJweDsg Zm9udC1zaX plOiAxM3B4 OyBjb2xvcj ogIzQ0NDsn PgogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg U2lnbiB1cC Bub3cgYW5k IGdldCBvdX IgZnJlZSBl Qm9vayAKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIDxiPl RoZSBDaGVj a2xpc3QgVm FsdWUgSW52 ZXN0b3Ig4o CUIEEgU21h cnRlciBXYX kgdG8gUGlj ayBTdG9ja3 M8L2I+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC EtLQogICAg ICAgICAgIC AgICAgICAg ICAgICA8ZG l2IHN0eWxl PSdtYXJnaW 4tdG9wOiAx NnB4OyBmb2 50LXNpemU6 IDE0cHg7IG NvbG9yOiAj NDQ0OyBmb2 50LWZhbWls eTogLWFwcG xlLXN5c3Rl bSwgQmxpbm tNYWNTeXN0 ZW1Gb250LC BTZWdvZSBV SSwgUm9ib3 RvLCBIZWx2 ZXRpY2EgTm V1ZSwgc2Fu cy1zZXJpZj sgbGluZS1o ZWlnaHQ6ID EuNjsnPgog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgSGF2 ZSB5b3UgaG VhcmQgYWJv dXQgb3VyIH Nob3J0IDxz dHJvbmcgc3 R5bGU9J2Zv bnQtd2VpZ2 h0OiA2MDA7 Jz5EYWlseS BWaWRlbyBO ZXdzbGV0dG VyPC9zdHJv bmc+PwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGEgaH JlZj0naHR0 cHM6Ly93d3 cuaW5zaWdo dGZ1bHZhbH VlLmNvbS9u ZXdzbGV0dG VyLnBocCcg dGFyZ2V0PS dfYmxhbmsn IHN0eWxlPS djb2xvcjog IzAwN0JGRj sgdGV4dC1k ZWNvcmF0aW 9uOiBub25l OyBmb250LX dlaWdodDog NTAwOyBtYX JnaW4tbGVm dDogNnB4Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgRmlu ZCBvdXQgbW 9yZQogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9hPgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgLS0+CiAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgIAogIC AgICAgIAog ICAgICAgID xzcGFuIGNs YXNzPSdibH VycmVkLXRl eHQnPgogIC AgICAgICAg ICBNUzRnUV dKaVZtIGxs SUhkaGN5Qm ogY21WaGRH VmtJRyBGek lHRWdjM0Jw IGJtOW1aaU JqYjIgMXdZ VzU1SUdaeS BiMjBnUVdK aWIzIFIwSU V4aFltOXkg WVhSdmNtbG xjeSBCcGJp QXlNREV6IE xDQnRZV3Rw Ym0gY2dhWF FnWVNCeSBa V3hoZEdsMl pXIHg1SUhs dmRXNW4gSU dOdmJYQmhi biBrZ1kyOX RjR0Z5IFpX UWdkRzhnYj MgUm9aWEp6 SUdsdSBJSF JvWlNCd2FH IEZ5YldGal pYVjAgYVdO aGJDQnBibS BSMWMzUnll UzQ4IFluSS tNaTRnVkcg aGxJRzVoYl dVZyBRV0pp Vm1sbElHIG x6SUdSbGNt bDIgWldRZ1 puSnZiUyBC aElHTnZiV0 pwIGJtRjBh Vzl1SUcgOW 1JSFJvWlNC MyBiM0prY3 lCQlltIEp2 ZEhRZ1lXNW sgSUhacGRH RnNhWCBSNU xqeGljajR6 IExpQkJZbU pXYVcgWGln Smx6SUdobC BZV1J4ZFdG eWRHIFZ5Y3 lCaGNtVWcg Ykc5allYUm xaQyBCcGJp Qk9iM0owIG FDQkRhR2xq WVcgZHZMQ0 JKYkd4cCBi bTlwY3k0OF luIEkrTkM0 Z1ZHaGwgSU dOdmJYQmhi biBrZ1pXMX diRzk1IGN5 QnZkbVZ5SU QgUTNMREF3 TUNCdyBaVz l3YkdVZ2Qy IDl5YkdSM2 FXUmwgSUdG dVpDQm9ZWC BNZ1lTQndj bVZ6IFpXNW paU0JwYmkg QnRiM0psSU hSbyBZVzRn TVRjd0lHIE 52ZFc1MGNt bGwgY3k0OF luSStOUyA0 Z1FXSmlWbW xsIDRvQ1pj eUJ3Y20gbH RZWEo1SUda diBZM1Z6SU dseklHIDl1 SUdSbGRtVn MgYjNCcGJt Y2dZVyA1a0 lHMWhiblZt IFlXTjBkWE pwYm0gY2dj R2hoY20xaC BZMlYxZEds allXIHdnY0 hKdlpIVmog ZEhNZ2FXNG dkRyBobElH RnlaV0Z6IE lHOW1JR2x0 YlggVnViMn h2WjNrcyBJ Rzl1WTI5c2 IyIGQ1TENC dVpYVnkgYj NOamFXVnVZ MiBVc0lIWn BjbTlzIGIy ZDVMQ0JoYm 0gUWdaMlZ1 WlhKaCBiQ0 J0WldScFky IGx1WlM0OF luSSsgTmk0 Z1ZHaGxJRy BOdmJYQmhi bm5pIGdKbH pJSFJ2Y0Mg MXpaV3hzYV c1biBJR1J5 ZFdjZ2FYIE 1nU0hWdGFY SmggTENCaE lHMWxaRyBs allYUnBiMj RnIGRYTmxa Q0IwYnkgQj BjbVZoZENC aCBkWFJ2YV cxdGRXIDVs SUdScGMyOX kgWkdWeWN5 QnpkVyBOb0 lHRnpJSEpv IFpYVnRZWF J2YVcgUWdZ WEowYUhKcC BkR2x6TENC d2MyIDl5YV dGemFYTXMg SUdGdVpDQk RjbSA5b2J1 S0FtWE1nIF pHbHpaV0Z6 WlMgNDhZbk krTnk0ZyBR V0ppVm1sbE lHIGhoY3lC dFlXUmwgSU hOcFoyNXBa bSBsallXNT BJR2x1IGRt VnpkRzFsYm 4gUnpJR2x1 SUhSbyBaU0 JtYVdWc1pD IEJ2WmlCaW FXOTAgWldO b2JtOXNiMi BkNUxDQndZ WEowIGFXTj FiR0Z5Ykgg a2dhVzRnZE dobCBJR0Z5 WldGeklHID ltSUdOaGJt TmwgY2lCaG JtUWdhVyAx dGRXNXZiRz luIGVTd2dk R2h5YjMgVm 5hQ0J3WVhK MCBibVZ5Yz JocGNIIE1n WVc1a0lHRm ogY1hWcGMy bDBhVyA5dW N5NDhZbkkr IE9DNGdTVz RnTWogQXhP U3dnUVdKaS BWbWxsSUdO dmJYIEJzWl hSbFpDQmgg SUNRMk15Qm lhVyB4c2FX OXVJR0ZqIG NYVnBjMmww YVcgOXVJRz ltSUVGcyBi R1Z5WjJGdU xDIEJoSUdk c2IySmggYk NCd2FHRnli VyBGalpYVj BhV05oIGJD QmpiMjF3WV cgNTVJR3R1 YjNkdSBJR1 p2Y2lCcGRI IE1nUW05MG IzZ2cgWW5K aGJtUXVQRy BKeVBqa3VJ RUZpIFlsWn BaU0JvWVgg TWdZU0J6ZE hKdiBibWNn WTI5dGJXIG wwYldWdWRD QjAgYnlCem RYTjBZVyBs dVlXSnBiR2 wwIGVTQmhi bVFnYUcgRn pJR0psWlc0 ZyBjbVZqYj JkdWFYIHBs WkNCbWIzSW cgYVhSeklH Vm1abSA5eW RITWdhVzRn IGNtVmtkV0 5wYm0gY2dh WFJ6SUdWdS BkbWx5YjI1 dFpXIDUwWV d3Z2FXMXcg WVdOMElIUm 9jbSA5MVoy Z2dhVzVwIG RHbGhkR2wy WlggTWdjM1 ZqYUNCaCBj eUIxYzJsdV p5IEJ5Wlc1 bGQyRmkgYk dVZ1pXNWxj bSBkNUlHRn VaQ0J5IFpX UjFZMmx1Wn kgQjNZWFJs Y2lCaiBiMj V6ZFcxd2RH IGx2Ymk0OF luSSsgTVRB dUlGUm9aUy BCamIyMXdZ VzU1IElHaG hjeUJoSUcg aHBjM1J2Y2 5rZyBiMlln Y0docGJHIE Z1ZEdoeWIz QjUgSUdGdV pDQm9ZWCBN Z1pHOXVZWF JsIFpDQnRh V3hzYVcgOX VjeUJ2WmlC ayBiMnhzWV hKeklIIFJ2 SUhaaGNtbH YgZFhNZ1ky RjFjMiBWek lHRnVaQ0J2 IGNtZGhibW w2WVggUnBi MjV6TENCcC BibU5zZFdS cGJtIGNnZE dodmMyVWcg Wm05amRYTm xaQyBCdmJp Qm9aV0ZzIG RHZ2dZMkZ5 WlMgd2daV1 IxWTJGMCBh Vzl1TENCaG JtIFFnY21W bWRXZGwgWl NCaGMzTnBj MyBSaGJtTm xMZz09CiAg ICAgICAgPC 9zcGFuPgog ICAgICAgIA ogICAgICAg IA==